Revive Therapeutics Ltd. · CSE:RVV
Revive Therapeutics — Investor Presentation (March 2020)
16 slides from Revive Therapeutics's investor presentation, March 2020

Slide 1: Psychedelic and Cannabis Life Sciences Company
Psychedelic and Cannabis Life Sciences Company Corporate Presentation March 2020 Revive Therapeutics Ltd. | Office: 905-605-5535 | E-mail: info@revivethera.com

Slide 2: Forward Looking Statements
FORWARD LOOKING STATEMENTS Certain statements contained in this presentation constitute forward-looking information within the meaning of securities laws. Forward- looking information may relate to our future outlook and anticipated events or results and may include statements regarding our future f

Slide 3: Revive Therapeutics
REVIVE THERAPEUTICS § Emerging cannabis and psychedelic life sciences company § Developing novel cannabis and psychedelic based therapies to treat liver, inflammatory, and rare diseases § Robust cannabis and psychedelic based product portfolio targeting multi-billion market opportunities § Significa

Slide 4: Pharmaceutical Strategy
PHARMACEUTICAL STRATEGY R&D of Psychedelics and Targeting Inflammation Novel Uses, Targeting FDA Designations: Cannabinoids and Rare Diseases Formulations, and Orphan, Fast track, Delivery System Breakthrough therapy and Rare pediatric diseases

Slide 5: Patent Portfolio
PATENT PORTFOLIO Psychedelic and Cannabis Based Patent Portfolio Title USPTO No. Status US 8642088 Issued on February 4, 2014 Cannabinoid Delivery System US 9545423 Issued on January 17, 2017 US 10104888 Issued on October 23, 2018 Use of Cannabidiol in the Treatment of Autoimmune Hepatitis US 824217

Slide 6: Delivery Technology
DELIVERY TECHNOLOGY § Delivering naturally extracted and synthetic psilocybin and cannabinoids § CANNABINOIDS - Novel combination of composites allowing for multiple delivery formats, potential synergistic and therapeutic effects § Tannin (plant-based) - antibacterial, antifungal, antioxidant and wo

Slide 7: Product Pipeline
PRODUCT PIPELINE Psychedelic and Cannabis Based Rare Disease Focus Stage of Regulatory Product Indication Market Development Status Autoimmune Received FDA + $100M CBD Filing IND Hepatitis Orphan Status 50k US Pop IRI Solid Organ Received FDA + $100M CBD Pre-clinical Transplants Orphan Status 20k US

Slide 8: Liver Disease Opportunity
LIVER DISEASE OPPORTUNITY § Potential $19.5Bn market by 2022; affecting +30mm people in U.S. § Focus on Autoimmune Hepatitis (AIH) and Nonalcoholic steatohepatitis (NASH) § AIH - rare disease (~ 76k patients in US) causing liver inflammation • Drawbacks of current therapies (steroids): Severe side e

Slide 9: Inflammatory Skin Disease Opportunity
INFLAMMATORY SKIN DISEASE OPPORTUNITY § Inflammatory skin diseases from immune system reactions Psoriasis § Unmet medical need requiring new treatment options • Current treatments are inadequate, have unwanted side effects profiles, and expensive Dermatitis § Dermatitis (Eczema) Market Opportunity •

Slide 10: Psychedelic Opportunity
PSYCHEDELIC OPPORTUNITY § Acquired Psilocin Pharma Corp. § PPC has novel methods of production of Psilocybin-based formulations § Developed six unique patent pending formulations for both natural and synthetically derived Psilocybin § Capsules (PSY-0.1), Sublingual Spray (PSY-0.2), Gel Cap (PSY-0.3)

Slide 11: Founder – Psilocin Pharma
FOUNDER – PSILOCIN PHARMA § Derrick Welsh § 14 years of Health Care experience, with the past 5 years in the Cannabis industry § Worked with several high profile publicly-traded Cannabis companies like Xanthic Bio Pharma and Green Growth Brands § Developed several patent pending formulations such as

Slide 12: Strategic Relationships
STRATEGIC RELATIONSHIPS Supply and collaboration Acquired March 2020 Research collaboration of truffles Psychedelic pharma for liver diseases License of cannabidiol for License of cannabinoid Licensed Dealer of treatment of Autoimmune delivery technology medical cannabis Hepatitis (R&D, Testing)

Slide 13: Value Driving Milestones in 2020
VALUE DRIVING MILESTONES IN 2020 Q1-2020 Complete acquisition of Psilocin Pharma Corp. Q2-2020 Submit IND for Phase 1/2a clinical study for CBD in the treatment of Autoimmune Hepatitis Q3-2020 Pre-IND meeting with FDA for Psilocybin in treatment of mental illness (indication undisclosed) Q2/3-2020 I

Slide 14: Significantly Undervalued
SIGNIFICANTLY UNDERVALUED 3.9 B 105 M 90 M 60 M 5M

Slide 15: Team
TEAM Management Board of Directors § Michael Frank § Michael Frank Chairman and CEO Chairman and CEO § Carmelo Marrelli § William Jackson Chief Financial Officer Director § Joshua Herman Director § Christian Scovenna Director § Andrew Lindzon Director

Slide 16: Stock Information
STOCK INFORMATION Ticker Symbols RVV (CSE) Share Price CAD $0.075 (March 10, 2020) 52 week High/Low CAD $0.135 / $0.025 Capital Structure 130,411,282 common shares (151,491,991 fully-diluted) Market Cap CAD ~ $10,000,000
Source: Internet Archive copy of revivethera.com
More decks from Revive Therapeutics Ltd.
Investor Presentation (August 2026)16 slides · August 2026
Investor Presentation (March 2026)13 slides · March 2026
Investor Presentation (February 2026)13 slides · February 2026
Investor Presentation (May 2025)15 slides · May 2025
Investor Presentation (February 2025)15 slides · February 2025
Investor Presentation (September 2024)15 slides · September 2024